Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00374179
Status:
COMPLETED
Last Update Posted:
2009-02-24
First Post:
2006-09-08
Brief Title:
CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkins Lymphoma
Sponsor:
Adnexus A Bristol-Myers Squibb RD Company
Organization:
Adnexus A Bristol-Myers Squibb RD Company
Study Overview
Official Title:
A Phase 1 Escalating Dose Study of CT-322 a VEGFR-2 Antagonist as Monotherapy in Patients With Advanced Solid Tumors and Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE CT-322 may stop the growth of solid tumors or non-Hodgkins lymphoma by stopping blood flow to the cancer
PURPOSE This phase I trial is studying the side effects of CT-322 in treating patients with advanced solid tumors or non-Hodgkins lymphoma
PURPOSE This phase I trial is studying the side effects of CT-322 in treating patients with advanced solid tumors or non-Hodgkins lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None